spacer
home > pmps > autumn 2009 > the new rule book for air cargo
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The New Rule Book for Air Cargo

 

The global air cargo industry has been buzzing about the new cargo-screening requirements which take effect in August 2010 for cargo originating in the US. Now, the Transportation Security Administration (TSA) is indicating that additional scrutiny will be required for shipments coming into the US as well.

This will be no easy task. In Europe alone, the pharmaceutical market represents a US$170 billion industry. One third of the top 15 global pharmaceutical sales leaders – GlaxoSmithKline, Novartis, Sanofi- Aventis, AstraZeneca and Hoffman- LaRoche – are headquartered in Europe and represent 32 per cent of the global pharmaceuticals sales market, or US$311.8 billion.

To ensure there is no disruption in the cold chain, carriers and forwarders are working The New Rule Book for Air Cargo Joe Reedy at American Airlines Cargo outlines what carriers need to know about new regulations for pharmaceutical cargo hand-in-hand to develop solutions for these global leaders and the industry as a whole.

AN EXCEPTION TO THE RULE

Before we examine solutions, let’s take a look at what has happened in the pharmaceutical industry up until now. As mentioned, pharmaceutical companies in the US and Europe, as well as around the world, recently felt the effect of the new TSA requirements. So far, two key dates have come and gone. The first was 1st February 2009. As of this date, 50 per cent of all cargo originating in the US needed to be screened at the piece level, which proved to be a manageable task for the industry. The second was 1st September 2009, which required the pharmaceutical and other industries shipping sensitive cargo to comply with the 50 per cent screening requirement.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Joe Reedy serves as Vice President of Cargo Sales and Marketing for American Airlines. In this role, Reedy directs American’s team of cargo sales professionals worldwide, in addition to the cargo marketing organisation. Joe formerly served as VP of Finance, overseeing the start of the company’s e-Business activity, including the AACargo.com website and an extensive process reengineering project aimed at streamlining American Airlines Cargo systems to enhance the customer experience. Joe received his MBA from the University of Texas, and has enjoyed a 20-year tenure with American Airlines.
spacer
Joe Reedy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement